Literature DB >> 30836977

Correction to: Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant.

Chen-Hua Yan1,2, Yu Wang1,2, Jing-Zhi Wang1, Yu-Hong Chen1, Yao Chen1, Feng-Rong Wang1, Yu-Qian Sun1, Xiao-Dong Mo1, Wei Han1, Huan Chen1, Xiao-Hui Zhang1,2, Lan-Ping Xu1, Kai-Yan Liu1,2, Xiao-Jun Huang3,4.   

Abstract

The original article [1] contains two errors in the MRD Testing sub-section of the Methods.

Entities:  

Year:  2019        PMID: 30836977      PMCID: PMC6402118          DOI: 10.1186/s13045-019-0715-8

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


Correction to: J Hematol Oncol (2016) 9:87 https://doi.org/10.1186/s13045-016-0319-5 The original article [1] contains two errors in the MRD Testing sub-section of the Methods: The description, “…by four-color flow cytometry (FCM)” was incorrect. The correct description should be “…by eight-color flow cytometry (FCM)”. The description, “LAIPs were detected by four-color FCM” was incorrect. The correct description should be “LAIPs were detected by eight-color FCM”.
  1 in total

1.  Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant.

Authors:  Chen-Hua Yan; Yu Wang; Jing-Zhi Wang; Yu-Hong Chen; Yao Chen; Feng-Rong Wang; Yu-Qian Sun; Xiao-Dong Mo; Wei Han; Huan Chen; Xiao-Hui Zhang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2016-09-15       Impact factor: 17.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.